Trials / Completed
CompletedNCT00159614
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-3902IV |
Timeline
- Start date
- 2005-09-01
- First posted
- 2005-09-12
- Last updated
- 2008-01-29
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00159614. Inclusion in this directory is not an endorsement.